Navigation Links
The Gladstone Institutes and iZumi Bio Announce Broad Partnership in Regenerative Medicine and Cardiovascular Disease
Date:6/16/2008

Kleiner-Perkins, Highland Capital Fund Company Focused on iPS Technology

SAN FRANCISCO, June 16 /PRNewswire/ -- iZumi Bio, Inc., and The J. David Gladstone Institutes, an independent non-profit biomedical research organization, have announced a major research collaboration and licensing agreement to focus on applications for induced pluripotent stem (iPS) cells.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080616/AQM126LOGO)

iPS cells are "reprogrammed" adult cells that have similar properties and potential to those of human embryonic stem (ES) cells, yet do not raise the same ethical concerns and can be generated in a patient-specific manner to avoid immune rejection.

"The Gladstone relationship with iZumi Bio combines our work in cardiovascular disease and stem cell science with first-class investors and an experienced management team," said Deepak Srivastava, MD, Director of the Gladstone Institute of Cardiovascular Disease (GICD). "It's an ideal model for advancing science in a focused, efficient way."

"Gladstone is emerging as a global leader in regenerative medicine and its applications to heart disease," said Thane Kreiner, PhD, iZumi Bio Chief Executive Officer. "This collaboration underscores our commitment and ability to translate the best research in iPS technology to products that address important unmet medical needs."

Elements of the broad partnership include iZumi Bio taking a license to certain Gladstone patents and sponsoring research related to iPS cells and cardiovascular disease. Dr. Srivastava will lead the research and will join iZumi Bio's scientific advisory board.

"We're delighted to add this important new company to our translational research partners," said Gladstone President, Robert W. Mahley, MD, PhD. "We look forward to developing iPS technology into treatments and cures."

About the Gladstone Institutes

The J. David Gladstone Institutes, affiliated with the University of California, San Francisco (UCSF), is dedicated to the health and welfare of humankind through research into the causes and prevention of some of the world's most devastating diseases. Gladstone is composed of the Gladstone Institute of Cardiovascular Disease, the Gladstone Institute of Virology and Immunology, and the Gladstone Institute of Neurological Disease. Two years ago, Gladstone formed the Center for Translational Research to create collaborations with biotechnology and pharmaceutical partners for preclinical development for its most promising therapeutic research candidates. More information can be found at http://www.gladstone.ucsf.edu.

About iZumi

iZumi Bio, Inc. was founded in 2007 and is funded by Kleiner Perkins Caufield and Byers and Highland Capital Partners. iZumi is using the power of induced pluripotent stem cells (iPS) to transform drug discovery and regenerative medicine. The name iZumi, which means "fountain of youth", was chosen to honor the Japanese origins of iPS technology. iZumi is located in the San Francisco Bay Area. More information will become available at http://www.izumibio.com.


'/>"/>
SOURCE iZumi Bio, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Gladstone scientists identify role of tiny RNAs in controlling stem cell fate
2. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
3. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
4. UNC-Chapel Hill, Hamner Institutes Announce Partnership to Accelerate Basic, Translational Research
5. National Institutes of Health Awards $25.5M Contract to SRA
6. EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board
7. Haemonetics Announces Launch of Faster Plasma Collection Protocol
8. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
9. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
10. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
11. Villa St. Benedict Announces New Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):